Efficacy of Mesenchymal Stem Cell Transplantation on Major Adverse Cardiovascular Events and Cardiac Function Indices in Patients with Chronic Heart Failure: a Meta-analysis of Randomized Controlled Trials

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Aug 22

PMID 39174960

Authors

Shahin Kavousi

Alireza Hosseinpour

Fateme Bahmanzadegan Jahromi

Armin Attar

Affiliations

Soon will be listed here.

Abstract

Background: The effects of mesenchymal stem cells (MSCs) on heart failure (HF) have been controversial. This study was conducted to investigate whether the transplantation of MSCs after HF could help improve clinical outcomes and myocardial performance indices.

Methods: Using a systematic approach, electronic databases were searched for randomized controlled trials (RCTs), which evaluated the transplantation of MSCs after HF. The outcomes owf interest included clinical outcomes and myocardial function indices. We also assessed the role of age, cause of heart failure, cell origin, cell number, type of donor (autologous/allogeneic), and route of cell delivery on these outcomes. Using the random-effects method, a relative risk (RR) or mean difference (MD) and their corresponding 95% confidence intervals (CI) were pooled.

Results: Seventeen RCTs including 1684 patients (927 and 757 patients in the intervention and control arms, respectively) were enrolled. The RR (95% CI) of mortality was 0.78 (0.62; 0.99, p = 0.04) in the MSC group compared to the controls. HF rehospitalization decreased in the MSC group (RR = 0.85 (0.71-1.01), p = 0.06), but this was only significant in those who received autologous MSCs (RR = 0.67 (0.49; 0.90), p = 0.008). LVEF was significantly increased among those who received MSC (MD = 3.38 (1.89; 4.87), p < 0.001). LVESV (MD = -9.14 (-13.25; -5.03), p < 0.001), LVEDV (MD = -8.34 -13.41; -3.27), p < 0.001), and scar size (standardized MD = -0.32 (-0.60; -0.05), p = 0.02) were significantly decreased. NYHA class (MD = -0.19 (-0.34; -0.06), p = 0.006), BNP level (standardized MD = -0.28 (-0.50; -0.06), p = 0.01), and MLHFQ (MD = -11.55 (-16.77; -6.33), p = 0.005) significantly decreased and 6-min walk test significantly improved (MD = 36.86 (11.22; 62.50), p = 0.001) in the MSC group. Trials were not affected by the participants' etiology of heart failure, while trials with the autologous source of cells, MSC doses lower than 100 million cells, and intracoronary injection performed significantly better in some of the outcomes.

Conclusion: Transplantation of MSCs for ischemic or dilated heart failure patients may reduce all-cause mortality and improve clinical condition. Moreover, this treatment would improve left ventricular function indices and reduce scar size.

References

Attar A, Bahmanzadegan Jahromi F, Kavousi S, Monabati A, Kazemi A . Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials. Stem Cell Res Ther. 2021; 12(1):600. PMC: 8650261. DOI: 10.1186/s13287-021-02667-1. View

Ulus A, Mungan C, Kurtoglu M, Celikkan F, Akyol M, Sucu M . Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial). Int J Stem Cells. 2020; 13(3):364-376. PMC: 7691850. DOI: 10.15283/ijsc20075. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Gan L, Liu Y, Cui D, Pan Y, Zheng L, Wan M . Dental Tissue-Derived Human Mesenchymal Stem Cells and Their Potential in Therapeutic Application. Stem Cells Int. 2020; 2020:8864572. PMC: 7482010. DOI: 10.1155/2020/8864572. View

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

Schmelzer E, McKeel D, Gerlach J . Characterization of Human Mesenchymal Stem Cells from Different Tissues and Their Membrane Encasement for Prospective Transplantation Therapies. Biomed Res Int. 2019; 2019:6376271. PMC: 6421008. DOI: 10.1155/2019/6376271. View

Bartolucci J, Verdugo F, Gonzalez P, Larrea R, Abarzua E, Goset C . Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord.... Circ Res. 2017; 121(10):1192-1204. PMC: 6372053. DOI: 10.1161/CIRCRESAHA.117.310712. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Qayyum A, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D . Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial. Eur J Heart Fail. 2023; 25(4):576-587. DOI: 10.1002/ejhf.2772. View

10.

Jansen of Lorkeers S, Eding J, Vesterinen H, van der Spoel T, Sena E, Duckers H . Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res. 2014; 116(1):80-6. DOI: 10.1161/CIRCRESAHA.116.304872. View

11.

Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J . Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61(23):2329-38. DOI: 10.1016/j.jacc.2013.02.071. View

12.

Mohyeddin-Bonab M, Mohamad-Hassani M, Alimoghaddam K, Sanatkar M, Gasemi M, Mirkhani H . Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med. 2007; 10(4):467-73. DOI: 07104/AIM.009. View

13.

Bartunek J, Terzic A, Davison B, Filippatos G, Radovanovic S, Beleslin B . Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2016; 38(9):648-660. PMC: 5381596. DOI: 10.1093/eurheartj/ehw543. View

14.

Wang J, Xia J, Huang R, Hu Y, Fan J, Shu Q . Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes via endorsement of macrophage polarization. Stem Cell Res Ther. 2020; 11(1):424. PMC: 7522905. DOI: 10.1186/s13287-020-01937-8. View

15.

Nowzari F, Zare M, Tanideh N, Meimandi-Parizi A, Kavousi S, Saneian S . Comparing the healing properties of intra-articular injection of human dental pulp stem cells and cell-free-secretome on induced knee osteoarthritis in male rats. Tissue Cell. 2023; 82:102055. DOI: 10.1016/j.tice.2023.102055. View

16.

Hosseinpour A, Kheshti F, Kazemi A, Attar A . Comparing the effect of bone marrow mono-nuclear cells with mesenchymal stem cells after acute myocardial infarction on improvement of left ventricular function: a meta-analysis of clinical trials. Stem Cell Res Ther. 2022; 13(1):203. PMC: 9109324. DOI: 10.1186/s13287-022-02883-3. View

17.

Xiao W, Guo S, Gao C, Dai G, Gao Y, Li M . A Randomized Comparative Study on the Efficacy of Intracoronary Infusion of Autologous Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells in Patients With Dilated Cardiomyopathy. Int Heart J. 2017; 58(2):238-244. DOI: 10.1536/ihj.16-328. View

18.

Bolli R, Mitrani R, Hare J, Pepine C, Perin E, Willerson J . A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021; 23(4):661-674. PMC: 8357352. DOI: 10.1002/ejhf.2178. View

19.

Perin E, Borow K, Silva G, DeMaria A, Marroquin O, Huang P . A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. Circ Res. 2015; 117(6):576-84. DOI: 10.1161/CIRCRESAHA.115.306332. View

20.

Pieper I, Smith R, Bishop J, Aldalati O, Chase A, Morgan G . Isolation of Mesenchymal Stromal Cells From Peripheral Blood of ST Elevation Myocardial Infarction Patients. Artif Organs. 2017; 41(7):654-666. DOI: 10.1111/aor.12829. View